BIND Therapeutics Inc., a clinical-stage nanomedicine platform company developing targeted and programmable therapeutics called AccurinsTM, announced today that BIND has been awarded the RUSNANOPRIZE 2013 for Innovative Development by the International Prize Award Committee.
This award recognizes BIND for its translation of state-of-the-art nanoparticle technology into clinical-stage development. The award ceremony was held at the Moscow International Forum for Open Innovation in Moscow on November 1, 2013.
"BIND is honored to receive this prestigious award and to be recognized by this world-wide panel of top scientific and business judges," said Scott Minick, BIND's CEO. "We are focused on leveraging BIND's medicinal nanoengineering platform to develop a pipeline of targeted therapeutics, called Accurins, with the potential to create innovative new medicines for patients in need worldwide."
BIND's co-founders, Professor Robert S. Langer Sc.D., Massachusetts Institute of Technology David H. Koch Institute Professor and Omid Farokhzad, M.D., Associate Professor at Harvard Medical School, have also been awarded the RUSNANOPRIZE for their research related to nanoparticle technologies for medical applications.
About the RUSNANOPRIZE
The RUSNANOPRIZE for Innovative Development is awarded each year by the International Prize Award Committee of the Russian Nanotechnology Corporation to researchers whose nanotechnology discoveries and innovations have been applied to production as well as to companies that have successfully implemented them. The members of the International Prize Award Committee are representatives of the scientific and innovative business community who are generally acknowledged to have achieved outstanding results in their fields. More information about the RUSNANOPRIZE can be found at http://www.rusnanoprize.ru/en/
About BIND Therapeutics
BIND Therapeutics is a clinical-stage nanomedicine platform company developing Accurins, its novel targeted therapeutics. BIND intends to leverage its medicinal nanoengineering platform to develop a pipeline of Accurins, initially in oncology, as well as Accurins in collaboration with biopharmaceutical companies. BIND's lead drug candidate, BIND-014, is an Accurin that targets PSMA and contains docetaxel, a clinically-validated and widely used cancer chemotherapy drug. BIND-014 is currently in Phase 2 clinical trials for non-small cell lung cancer and metastatic castrate resistant prostate cancer. To date in 2013, BIND has announced collaborations with Amgen, Inc., Pfizer Inc. and AstraZeneca AB to develop Accurins based on therapeutic payloads from their product pipelines. BIND's platform originated from the pioneering nanotechnology research at the Massachusetts Institute of Technology and Brigham and Women's Hospital/Harvard Medical School of BIND's scientific founders and directors Dr. Robert Langer and Dr. Omid Farokhzad.